Nasdaq nmra.

Sep 21, 2023 · Investors can buy NMRA even cheaper than Gosebruch did, with shares changing hands as low as $10.01 at last check today -- that's 20.7% under Gosebruch's purchase price. VIDEO: Thursday 9/21 ... Uncover the latest insider trading activity for Neumora Therapeutics, Inc. (NMRA). Know which insiders are buying and selling along with top shareholders and ownership breakdown. Dashboard Markets Discover Watchlist Portfolios Screener. Neumora Therapeutics, Inc. NasdaqGS:NMRA Stock Report. Mkt Cap: US$1.8b.The stock’s previous close on October 9, 2023, was $12.14, but it opened higher on October 10, 2023, at $12.62. Throughout the trading day, NMRA stock experienced a range of prices, with the lowest price recorded at $11.25 and the highest price reached at $13.13. The trading volume on October 10, 2023, was significantly higher than …6 Wall Street analysts have issued 12-month price objectives for Neumora Therapeutics' stock. Their NMRA share price targets range from $18.00 to $26.00. On …

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the ...WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ...Shares of Neumora Therapeutics (NMRA 0.41%) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence.

Neumora Therapeutics, Inc. Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study. Nov 28. Neumora Therapeutics, Inc. has completed an IPO in the amount of $250.07 million. Sep 16. Earnings and Revenue Growth Forecasts. NasdaqGS:NMRA - Analysts future estimates and past financials data (USD Millions) DateQuais ferramentas de análise técnica podem ser usadas para analisar Neumora Therapeutics, Inc.? Confira vários osciladores, médias móveis e outros indicadores …

NMRA-266 is an investigational positive allosteric modulator of the M4 muscarinic receptor subtype, a clinically validated target for the treatment of schizophrenia. Neumora exclusively licensed ...Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the ...Neumora Therapeutics, Inc. (NASDAQ:NMRA) has filed proposed terms to raise $250 million from the sale of its common stock in an IPO, according to an amended SEC registration statement.Neumora Therapeutics, Inc. Common Stock (NMRA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.The latest price target for . Neumora Therapeutics (NASDAQ: NMRA) was reported by JP Morgan on November 8, 2023.The analyst firm set a price target for $20.00 expecting NMRA to rise to within 12 ...

Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, NMRA-CK1d, NMRA-NLRP3, and NMRA-GCase. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-266 is a positive allosteric modulator of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia and other neuropsychiatric …

Neumora Therapeutics (NASDAQ: NMRA) is owned by 23.77% institutional shareholders, 65.44% Neumora Therapeutics insiders, and 10.79% retail investors. Amgen Inc is the largest individual Neumora Therapeutics shareholder, owning 35.37M shares representing 23.16% of the company. Amgen Inc's Neumora Therapeutics shares are currently valued …

View the latest NMRA social media trends at MarketBeat. Skip to main content. S&P 500 4,514.02. DOW 34,947.28. QQQ 386.04. 3 large caps with red hot RSIs with upside. ... This page (NASDAQ:NMRA) was last updated on 11/18/2023 by MarketBeat.com Staff. Adding Choose a watchlist: Watchlist. Cancel AddingNeumora Therapeutics (NASDAQ:NMRA – Get Free Report) last issued its earnings results on Wednesday, November 1st. The company reported ($1.14) earnings per share for the quarter, missing the ...Nov 1, 2023 · Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the global brain disease ... Canopy Growth Corporation Common Shares. $1.275 -0.065 -4.85%. Neumora Therapeutics, Inc. Common Stock (NMRA) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US ... NMRA Neumora Therapeutics, Inc. Stock Price & Overview. Follow 212 followers. $12.250.00 (0.00%)11:37 AM 12/01/23. NASDAQ | $USD | Realtime. Summary · Ratings ...On Wednesday, Neumora Therapeutics Inc. [NASDAQ: NMRA] rose 1.88% to $11.91. The stock’s lowest price that day was $11.76, but it reached a high of $12.14 in the same session. During the last five days, there has been a drop of approximately -0.83%. Over the course of the year, Neumora Therapeutics Inc. shares have dropped approximately -26.71%.Neumora Therapeutics (NASDAQ: NMRA), a biotech company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, went public on September 15th with ...

Victor J. Blue/Bloomberg. Shares of Watertown biotech Neumora Therapeutics retreated 4.4 percent Friday, in the company’s debut on the Nasdaq stock exchange, after it raised $250 million in an ...WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the third quarter ended September 30, 2023 and provided ... (NMRA-140) is a highly selective, novel, …NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia WATERTOWN, Mass., Nov. 27, 2023 (GLOBE ...Uncover the latest insider trading activity for Neumora Therapeutics, Inc. (NMRA). Know which insiders are buying and selling along with top shareholders and ownership breakdown. Dashboard Markets Discover Watchlist Portfolios Screener. Neumora Therapeutics, Inc. NasdaqGS:NMRA Stock Report. Mkt Cap: US$1.8b.Oct 10, 2023 · For Neumora Therapeutics Inc (NASDAQ:NMRA), William Blair initiated coverage, by setting the current rating at Outperform. The stock has a 52-week-high of $17.74 and a 52-week-low of $9.90. Nov 27, 2023 · NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders.

Complete Neumora Therapeutics Inc. stock information by Barron's. View real-time NMRA stock price and news, along with industry-best analysis.(NASDAQ: NMRA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.21%. What is NMRA's Price Target? According to 5 Wall Street analyst s that have issued a 1 year NMRA price target, the average NMRA price target is $22.00 , with the highest NMRA stock price forecast at $26.00 and the lowest NMRA stock ...

Nov 27, 2023 · NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia WATERTOWN, Mass., Nov. 27, 2023 (GLOBE ... NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. “The ...1.55. EBIT. -130.9. -237.31. Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual ( 10-K) and quarterly ( 10-Q) reports submitted to the Securities and Exchange Commission (SEC). Detailed annual and quarterly income statement for Neumora Therapeutics, Inc. (NMRA). See many years of revenue, …Nov 22, 2023 · Navacaprant is an investigational once-daily oral medication that is designed to modulate the dopamine and reward processing pathways. Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, NMRA-CK1d, NMRA-NLRP3, and NMRA-GCase. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). Sep 15, 2023 · Find the latest Earnings Report Date for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com. Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.

Posted by Defense World Staff on Nov 24th, 2023. Shares of Neumora Therapeutics, Inc. ( NASDAQ:NMRA – Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed ...

View Your Watchlist. Stock analysis for Neumora Therapeutics Inc (NMRA:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and …

NASDAQ: NMRA · IEX Real-Time Price · USD. Add to Watchlist 11.92 +0.01 (0.08%) Nov 24, 2023, 4:30 PM EST - Market closed. Overview; Financials; ... Stock Price Forecast. According to 5 stock analysts, the average 12-month stock price forecast for NMRA stock stock is $22, which predicts an increase of 84.56%. The lowest target is $18 …Neumora Therapeutics IPO Registration Document (S-1) Neumora Therapeutics has filed to go public with an IPO on the NASDAQ. 3 months ago - SEC. …The latest price target for . Neumora Therapeutics (NASDAQ: NMRA) was reported by JP Morgan on November 8, 2023.The analyst firm set a price target for $20.00 expecting NMRA to rise to within 12 ... How much institutional buying is happening at Neumora Therapeutics? Institutional investors have bought a total of 11,743,056 shares in the last 24 months. This purchase volume represents approximately $165.69M in transactions. This page (NASDAQ:NMRA) was last updated on 11/28/2023 by MarketBeat.com Staff.Shares of Neumora Therapeutics, Inc. ( NASDAQ:NMRA – Get Free Report) traded up 4.6% on Friday . The stock traded as high as $11.21 and last traded at $11.09. 32,521 shares were traded during ...The Watertown, MA-based Neumora Therapeutics (NASDAQ:NMRA), a Phase 3 biotech developing therapies for brain diseases has priced its initial public offering of 14.71 million shares of its common ...WATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug ...Neumora Therapeutics (NASDAQ:NMRA) shares are up over 15% this morning. 10 Top Losers Vivos Therapeutics (NASDAQ: VVOS ) stock is plummeting nearly 34% after a massive rally yesterday on FDA news .WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ...US6409791000. Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action ...WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ...

See the latest Neumora Therapeutics Inc stock price (NMRA:XNAS), related news, valuation, dividends and more to help you make your investing decisions.VinFast Auto Ltd. (NASDAQ:VFS) gained 13.6% to $12.73 following a report suggesting the company is planning to set up a manufacturing plant in India. Neumora Therapeutics, Inc. (NASDAQ:NMRA ...Insiders and Institutions Are Buying These Robot Stocks. This page (NASDAQ:NMRA) was last updated on 11/24/2023 by MarketBeat.com Staff. Adding. Choose a ...WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ...Instagram:https://instagram. moving insurance ratesbest site to track stockssplunk stock forecastpff holdings 3 hari yang lalu ... Read Neumora Therapeutics, Inc. (NASDAQ:NMRA) to Post FY2023 Earnings of ($4.25) Per Share, William Blair Forecasts at Defense World.View NMRA historial stock data and compare to other stocks and exchanges. ... Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. nyse hhhishares core msci eafe etf NASDAQ: NMRA · IEX Real-Time Price · USD. Add to Watchlist 11.92 +0.01 (0.08%) Nov 24, 2023, 4:30 PM EST - Market closed. Overview; Financials; ... Stock Price Forecast. According to 5 stock analysts, the average 12-month stock price forecast for NMRA stock stock is $22, which predicts an increase of 84.56%. The lowest target is $18 …Neumora Therapeutics, Inc. Common Stock (NMRA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. charles schwab trading platform vs thinkorswim Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the ...Sep 15, 2023 · Find the latest Earnings Report Date for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com. Sep 28, 2023 · VinFast Auto Ltd. (NASDAQ:VFS) gained 13.6% to $12.73 following a report suggesting the company is planning to set up a manufacturing plant in India. Neumora Therapeutics, Inc. (NASDAQ:NMRA ...